Kisunla (Donanemab) |  Leqembi (Lecanemab) | |
|---|---|---|
Drug Class | Monoclonal antibody targeting beta-amyloid. | Monoclonal antibody targeting beta-amyloid. |
Approval | July 2, 2024 | July 2023 |
Infusions | 1 / month | 2 / month |
If scans show clearing | Often OK to stop treatment after 6 – 18 months | Continue treatment anyway |
Cost | $32,000 / year | $26,000 / year |
At 18 months, improved cognitive decline | 35% | 30% |
More Convenient Injectable Version | No | Expected mid-2025 |
Official # of Patients Treated | 0 | 2,000 |
Side effects: Adverse Events | 17.4% | 21.3% |
Cost of drug (After Medicare Part B deductible, besides non-drug costs) | About 20% (Around $6,400 / year) | About 20% ($5,300 /year) |
/*! elementor – v3.22.0 – 26-06-2024 */
.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}
Kisunla vs. Leqembi: A Comparative Overview
Let’s compare Kisunla and Leqembi, two drugs used in the treatment of Alzheimer’s disease:
1. Drug Class:
-
- Kisunla:
-
- Belongs to a new class of drugs designed to slow the progression of Alzheimer’s disease.
-
- A monoclonal antibody that targets beta-amyloid, the toxic protein that accumulates in the brains of Alzheimer’s patients, forming plaques that disrupt normal brain signaling.
-
- Kisunla:
-
- Leqembi:
-
- Also a monoclonal antibody targeting beta-amyloid.
-
- Approved last year for certain patients with early Alzheimer’s disease.
-
- Leqembi:
2. Approval:
-
- Kisunla:
-
- Infused once a month.
-
- Kisunla:
-
- Leqembi:
-
- Approved earlier.
-
- Leqembi:
3. Effectiveness:
-
- Kisunla:
-
- May slow declines in memory and thinking skills in early-stage Alzheimer’s patients.
-
- Cannot reverse memory loss or other symptoms.
-
- Not a cure.
-
- Kisunla:
-
- Leqembi:
-
- Similar effects to Kisunla.
-
- Leqembi:
4. Brain Scans:
-
- Kisunla:
-
- Patients can stop taking the drug after PET brain scans show minimal beta-amyloid levels (unlike Leqembi, where patients continue treatment).
-
- Kisunla:
Remember that neither drug can reverse existing brain damage, and benefits are modest. Consult your doctor to determine the best treatment for your specific situation. 
Learn more:
/*! elementor – v3.22.0 – 26-06-2024 */
.elementor-widget-video .elementor-widget-container{overflow:hidden;transform:translateZ(0)}.elementor-widget-video .elementor-wrapper{aspect-ratio:var(–video-aspect-ratio)}.elementor-widget-video .elementor-wrapper iframe,.elementor-widget-video .elementor-wrapper video{height:100%;width:100%;display:flex;border:none;background-color:#000}@supports not (aspect-ratio:1/1){.elementor-widget-video .elementor-wrapper{position:relative;overflow:hidden;height:0;padding-bottom:calc(100% / var(–video-aspect-ratio))}.elementor-widget-video .elementor-wrapper iframe,.elementor-widget-video .elementor-wrapper video{position:absolute;top:0;right:0;bottom:0;left:0}}.elementor-widget-video .elementor-open-inline .elementor-custom-embed-image-overlay{position:absolute;top:0;right:0;bottom:0;left:0;background-size:cover;background-position:50%}.elementor-widget-video .elementor-custom-embed-image-overlay{cursor:pointer;text-align:center}.elementor-widget-video .elementor-custom-embed-image-overlay:hover .elementor-custom-embed-play i{opacity:1}.elementor-widget-video .elementor-custom-embed-image-overlay img{display:block;width:100%;aspect-ratio:var(–video-aspect-ratio);-o-object-fit:cover;object-fit:cover;-o-object-position:center center;object-position:center center}@supports not (aspect-ratio:1/1){.elementor-widget-video .elementor-custom-embed-image-overlay{position:relative;overflow:hidden;height:0;padding-bottom:calc(100% / var(–video-aspect-ratio))}.elementor-widget-video .elementor-custom-embed-image-overlay img{position:absolute;top:0;right:0;bottom:0;left:0}}.elementor-widget-video .e-hosted-video .elementor-video{-o-object-fit:cover;object-fit:cover}.e-con-inner>.elementor-widget-video,.e-con>.elementor-widget-video{width:var(–container-widget-width);–flex-grow:var(–container-widget-flex-grow)}
The post Kisunla Vs. Leqembi: The New Alzheimer’s Drugs appeared first on Alzheimer's & Dementia Weekly.
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by healthlydays.
Publisher: Source link
Publisher: Source link
